The US Bankruptcy Court approved the first amended disclosure statement of Melinta Therapeutics, Inc. on February 25, 2020. The debtor had filed its amended disclosure statement in the Court on February 19, 2020. February 20, 2020 has been fixed as voting record date.

The deadline to vote on the plan is March 30, 2020 and the plan objection deadline is March 26, 2020. The confirmation hearing for the plan has been scheduled for April 2, 2020.